1. Home
  2. Africa

Italian AIDS vaccine trials to include Africa

Italy says it plans to expand its second round of AIDS vaccine research to parts of Africa, after a successful first round conducted between November 2003 and 2004. Researchers at Italy's National Health Institute said their vaccine was safe and well-tolerated by all respondents, some of whom were HIV-positive. Noting that only a dozen of the 30 vaccines being researched globally had made it to Phase II testing, the US-based AIDS Vaccine Advocacy Coalition (AVAC) hailed the Italian research as "very important". Reuters quoted AVAC executive director, Mitchell Warren, as saying: "Are they going to produce the first AIDS vaccine? We don't know. But finding out what doesn't work right now is almost as important as finding out what works." Italy is holding talks with the European Union and private investors to accumulate the estimated US $59 million required for funding the second-phase trials.

This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions

Share this article

Get the day’s top headlines in your inbox every morning

Starting at just $5 a month, you can become a member of The New Humanitarian and receive our premium newsletter, DAWNS Digest.

DAWNS Digest has been the trusted essential morning read for global aid and foreign policy professionals for more than 10 years.

Government, media, global governance organisations, NGOs, academics, and more subscribe to DAWNS to receive the day’s top global headlines of news and analysis in their inboxes every weekday morning.

It’s the perfect way to start your day.

Become a member of The New Humanitarian today and you’ll automatically be subscribed to DAWNS Digest – free of charge.

Become a member of The New Humanitarian

Support our journalism and become more involved in our community. Help us deliver informative, accessible, independent journalism that you can trust and provides accountability to the millions of people affected by crises worldwide.

Join